SCHEMBL376491

SCHEMBL376491

N#Cc1ccc(N2CCC(=O)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.59
TP53 P04637 1/20 0.59
CHRNA10 Q9GZZ6 1/20 0.50
CHRNA9 Q9UGM1 1/20 0.50
POLB P06746 2/20 0.45
PANK3 Q9H999 1/20 0.45
CHEK1 O14757 1/20 0.43
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
HSD11B1 P28845 1/20 0.42
GAA P10253 1/20 0.41
ELANE P08246 1/20 0.41
CYP11B2 P19099 1/20 0.41
HTR7 P34969 1/20 0.40
HRH3 Q9Y5N1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21360410 0.93 KDM4E (0.53) KDM4ETP53CHRNA10CHRNA9POLB
Propene SCHEMBL7716012 0.90 KDM4E (0.50) KDM4ETP53CHRNA10CHRNA9POLB
SCHEMBL2384959 0.83 KDM4E (0.80) KDM4ETP53CHRNA10CHRNA9POLB
SCHEMBL27580893 0.82 KDM4E (0.39) KDM4ETP53CHRNA10CHRNA9
SCHEMBL6074530 0.82 ALDH1A1 (0.52) TP53POLB
SCHEMBL12295378 0.81 KDM4E (0.59) KDM4ETP53CHRNA10CHRNA9POLB
SCHEMBL154178 0.79 KDM4E (0.68) KDM4ETP53CHRNA10CHRNA9POLB
SCHEMBL7402909 0.79 KDM4E (0.68) KDM4ETP53CHRNA10CHRNA9POLB
SCHEMBL14637410 0.79 KDM4E (0.49) KDM4ETP53CHRNA10CHRNA9POLB
SCHEMBL7487913 0.79 DRD2 (0.66)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364232-B2 Antibacterial compounds JANSSEN SCIENCES IRELAND UC (IE) 2019-07-30 US disclosed
US-20180186768-A1 Antibacterial Compounds JANSSEN SCIENCES IRELAND UC (IE) 2018-07-05 US disclosed
EP-2547678-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2016-03-16 EP disclosed
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US disclosed
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US disclosed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US disclosed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 US disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 US disclosed
US-5276049-A Treatment of thrombosis DR. KARL THOMAE GMBH (DE) 1994-01-04 US disclosed
US-5260318-A Phenylpiperidylamines and drugs containing them BASF AKTIENGESELLSCHAFT (DE) 1993-11-09 US disclosed
EP-0503411-A1 Substituted N-phenylpiperidines and medicaments thereof BASF Aktiengesellschaft (DE) 1992-09-16 EP disclosed
EP-0503548-A1 Cyclic urea derivatives, medicaments contaning them and process for their preparation Dr. Karl Thomae GmbH (DE) 1992-09-16 EP disclosed
EP-0481299-A2 N-phenyl-piperidyl-4-amines and drugs containing them BASF Aktiengesellschaft (DE) 1992-04-22 EP disclosed
US-4902685-A ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1990-02-20 US disclosed
US-4902800-A USED AS ANTIINFLAMMATORY AGENTS AND IN TREATMENT OF DISEASE STATES INVOLVING ENZYMATIC TISSUE DESTRUCTION AMERICAN HOME PRODUCTS CORPORATION (US) 1990-02-20 US disclosed
US-4894374-A ANTIINFLAMMATORY AGENTS, ENZYME TISSUE DESTRUCTION, INTERLEUKIN INHIBITORS AMERICAN HOME PRODUCTS CORPORATION (US) 1990-01-16 US disclosed
US-4808612-A ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1989-02-28 US disclosed
US-4748246-A INTERLEUKIN ANTAGONISTS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1988-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10364232-B2 Antibacterial compounds FDPS, SQOR, NDUFS3 KDM4E 3387/4885TP53 3030/4885CHRNA10 4875/4885
US-20180186768-A1 Antibacterial Compounds FDPS, SQOR, NDUFS3 KDM4E 3387/4885TP53 3030/4885CHRNA10 4875/4885
US-20130065884-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 KDM4E 4439/4885TP53 2233/4885CHRNA10 4873/4885
US-20140155387-A1 Anti-Inflammation Compounds NR0B1, NR0B2, NR5A2 KDM4E 2886/4885TP53 4754/4885CHRNA10 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.